{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:35:40Z","timestamp":1768815340780,"version":"3.49.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.cgh.2019.05.057","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T20:58:57Z","timestamp":1560200337000},"page":"747-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-8214","authenticated-orcid":false,"given":"Pimsiri","family":"Sripongpun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajitha","family":"Mannalithara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Y.","family":"Kwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Ray","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2019.05.057_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.05.057_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.05.057_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u202fweeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2019.05.057_bib4","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/j.ackd.2015.06.001","article-title":"Chronic kidney disease and related long-term complications after liver transplantation","volume":"22","author":"Sharma","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.cgh.2019.05.057_bib5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cgh.2019.05.057_bib6","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S0168-8278(18)30392-1","article-title":"Safety and efficacy at 1 year after switching from tenofovir disoproxil fumurate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use","volume":"68","author":"Gane","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"S1","key":"10.1016\/j.cgh.2019.05.057_bib7","first-page":"914A","article-title":"Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B","volume":"64","author":"Fung","year":"2016","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.cgh.2019.05.057_bib8","first-page":"711A","article-title":"Safety and efficacy at 1 year in post liver transplant patients with chronic kidney disease receiving tenofovir alafenamide for hbv prophylaxis","volume":"68","author":"Gane","year":"2018","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519306093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519306093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:30:54Z","timestamp":1761543054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356519306093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1542356519306093"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2019.05.057","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.05.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}